Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-45035 in Healthy Participants and Patients With Autoimmune Dermatological Diseases
NCT06342713Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 3
01
Overview
Phase 1, randomised trial of BGB-45035 in atopic dermatitis (AD) and prurigo nodularis (PN) (7 arms), sponsored by BeiGene. Primary endpoints: Number of Participants Experiencing Adverse Events up to 16 weeks, Clinically significant changes from baseline in clinical laboratory values at 1 month and 2 more. Started Jun 2024; status: completed.
02
Drugs
BGB-45035
03
Conditions
atopic dermatitis (AD)prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06342713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342713.